278 related articles for article (PubMed ID: 26061388)
21. Discovery of biaryl carboxylamides as potent RORγ inverse agonists.
Chao J; Enyedy I; Van Vloten K; Marcotte D; Guertin K; Hutchings R; Powell N; Jones H; Bohnert T; Peng CC; Silvian L; Hong VS; Little K; Banerjee D; Peng L; Taveras A; Viney JL; Fontenot J
Bioorg Med Chem Lett; 2015 Aug; 25(15):2991-7. PubMed ID: 26048806
[TBL] [Abstract][Full Text] [Related]
22. Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.
Zhang Y; Wu X; Xue X; Li C; Wang J; Wang R; Zhang C; Wang C; Shi Y; Zou L; Li Q; Huang Z; Hao X; Loomes K; Wu D; Chen HW; Xu J; Xu Y
J Med Chem; 2019 May; 62(9):4716-4730. PubMed ID: 30964293
[TBL] [Abstract][Full Text] [Related]
23. Discovery of 1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide analogs as new RORC modulators.
Muegge I; Collin D; Cook B; Hill-Drzewi M; Horan J; Kugler S; Labadia M; Li X; Smith L; Zhang Y
Bioorg Med Chem Lett; 2015 May; 25(9):1892-5. PubMed ID: 25840886
[TBL] [Abstract][Full Text] [Related]
24. Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
Gege C; Schlüter T; Hoffmann T
Bioorg Med Chem Lett; 2014 Nov; 24(22):5265-7. PubMed ID: 25305688
[TBL] [Abstract][Full Text] [Related]
25. Structural determinant for inducing RORgamma specific inverse agonism triggered by a synthetic benzoxazinone ligand.
Marcotte DJ; Liu Y; Little K; Jones JH; Powell NA; Wildes CP; Silvian LF; Chodaparambil JV
BMC Struct Biol; 2016 Jun; 16(1):7. PubMed ID: 27246200
[TBL] [Abstract][Full Text] [Related]
26. Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating Cancer.
Aicher TD; Van Huis CA; Hurd AR; Skalitzky DJ; Taylor CB; Beleh OM; Glick G; Toogood PL; Yang B; Zheng T; Huo C; Gao J; Qiao C; Tian X; Zhang J; Demock K; Hao LY; Lesch CA; Morgan RW; Moisan J; Wang Y; Scatina J; Paulos CM; Zou W; Carter LL; Hu X
J Med Chem; 2021 Sep; 64(18):13410-13428. PubMed ID: 34499493
[TBL] [Abstract][Full Text] [Related]
27. Discovery of orally efficacious RORγt inverse agonists, part 1: Identification of novel phenylglycinamides as lead scaffolds.
Shirai J; Tomata Y; Kono M; Ochida A; Fukase Y; Sato A; Masada S; Kawamoto T; Yonemori K; Koyama R; Nakagawa H; Nakayama M; Uga K; Shibata A; Koga K; Okui T; Shirasaki M; Skene R; Sang B; Hoffman I; Lane W; Fujitani Y; Yamasaki M; Yamamoto S
Bioorg Med Chem; 2018 Jan; 26(2):483-500. PubMed ID: 29262987
[TBL] [Abstract][Full Text] [Related]
28. Recent progress on nuclear receptor RORγ modulators.
Cyr P; Bronner SM; Crawford JJ
Bioorg Med Chem Lett; 2016 Sep; 26(18):4387-4393. PubMed ID: 27542308
[TBL] [Abstract][Full Text] [Related]
29. Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.
Gege C; Albers M; Kinzel O; Kleymann G; Schlüter T; Steeneck C; Hoffmann T; Xue X; Cummings MD; Spurlino J; Milligan C; Fourie AM; Edwards JP; Leonard K; Coe K; Scott B; Pippel D; Goldberg SD
Bioorg Med Chem Lett; 2020 Jun; 30(12):127205. PubMed ID: 32336498
[TBL] [Abstract][Full Text] [Related]
30. Potent and Orally Bioavailable Inverse Agonists of RORγt Resulting from Structure-Based Design.
Narjes F; Xue Y; von Berg S; Malmberg J; Llinas A; Olsson RI; Jirholt J; Grindebacke H; Leffler A; Hossain N; Lepistö M; Thunberg L; Leek H; Aagaard A; McPheat J; Hansson EL; Bäck E; Tångefjord S; Chen R; Xiong Y; Hongbin G; Hansson TG
J Med Chem; 2018 Sep; 61(17):7796-7813. PubMed ID: 30095900
[TBL] [Abstract][Full Text] [Related]
31. Discovery of 2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide derivatives as new RORγ inhibitors using virtual screening, synthesis and biological evaluation.
Zhang Y; Xue X; Jin X; Song Y; Li J; Luo X; Song M; Yan W; Song H; Xu Y
Eur J Med Chem; 2014 May; 78():431-41. PubMed ID: 24704616
[TBL] [Abstract][Full Text] [Related]
32. Discovery of orally efficacious RORγt inverse agonists. Part 2: Design, synthesis, and biological evaluation of novel tetrahydroisoquinoline derivatives.
Kono M; Oda T; Tawada M; Imada T; Banno Y; Taya N; Kawamoto T; Tokuhara H; Tomata Y; Ishii N; Ochida A; Fukase Y; Yukawa T; Fukumoto S; Watanabe H; Uga K; Shibata A; Nakagawa H; Shirasaki M; Fujitani Y; Yamasaki M; Shirai J; Yamamoto S
Bioorg Med Chem; 2018 Jan; 26(2):470-482. PubMed ID: 29258712
[TBL] [Abstract][Full Text] [Related]
33. Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.
Shaikh NS; Iyer JP; Munot YS; Mukhopadhyay PP; Raje AA; Nagaraj R; Jamdar V; Gavhane R; Lohote M; Sherkar P; Bala M; Petla R; Meru A; Umrani D; Rouduri S; Joshi S; Reddy S; Kandikere V; Bhuniya D; Kulkarni B; Mookhtiar KA
Bioorg Med Chem Lett; 2019 Aug; 29(16):2208-2217. PubMed ID: 31272795
[TBL] [Abstract][Full Text] [Related]
34. Discovery of (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidines as novel RORγt inverse agonists.
Jiang B; Duan JJ; Stachura S; Karmakar A; Hemagiri H; Raut DK; Gupta AK; Weigelt CA; Khan J; Sack JS; Wu DR; Yarde M; Shen DR; Galella MA; Mathur A; Zhao Q; Salter-Cid LM; Carter PH; Dhar TGM
Bioorg Med Chem Lett; 2020 Sep; 30(17):127392. PubMed ID: 32738966
[TBL] [Abstract][Full Text] [Related]
35. Discovery of phenoxyindazoles and phenylthioindazoles as RORγ inverse agonists.
Ouvry G; Bouix-Peter C; Ciesielski F; Chantalat L; Christin O; Comino C; Duvert D; Feret C; Harris CS; Lamy L; Luzy AP; Musicki B; Orfila D; Pascau J; Parnet V; Perrin A; Pierre R; Polge G; Raffin C; Rival Y; Taquet N; Thoreau E; Hennequin LF
Bioorg Med Chem Lett; 2016 Dec; 26(23):5802-5808. PubMed ID: 27815118
[TBL] [Abstract][Full Text] [Related]
36. Identification of novel quinazolinedione derivatives as RORγt inverse agonist.
Fukase Y; Sato A; Tomata Y; Ochida A; Kono M; Yonemori K; Koga K; Okui T; Yamasaki M; Fujitani Y; Nakagawa H; Koyama R; Nakayama M; Skene R; Sang BC; Hoffman I; Shirai J; Yamamoto S
Bioorg Med Chem; 2018 Feb; 26(3):721-736. PubMed ID: 29342416
[TBL] [Abstract][Full Text] [Related]
37. Discovery of 6-Oxo-4-phenyl-hexanoic acid derivatives as RORγt inverse agonists showing favorable ADME profile.
Nakajima R; Oono H; Kumazawa K; Ida T; Hirata J; White RD; Min X; Guzman-Perez A; Wang Z; Symons A; Singh SK; Mothe SR; Belyakov S; Chakrabarti A; Shuto S
Bioorg Med Chem Lett; 2021 Mar; 36():127786. PubMed ID: 33493627
[TBL] [Abstract][Full Text] [Related]
38. Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (RORγ/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity.
Gong H; Weinstein DS; Lu Z; Duan JJ; Stachura S; Haque L; Karmakar A; Hemagiri H; Raut DK; Gupta AK; Khan J; Camac D; Sack JS; Pudzianowski A; Wu DR; Yarde M; Shen DR; Borowski V; Xie JH; Sun H; D'Arienzo C; Dabros M; Galella MA; Wang F; Weigelt CA; Zhao Q; Foster W; Somerville JE; Salter-Cid LM; Barrish JC; Carter PH; Dhar TGM
Bioorg Med Chem Lett; 2018 Jan; 28(2):85-93. PubMed ID: 29233651
[TBL] [Abstract][Full Text] [Related]
39. Discovery of novel pyrazole-containing benzamides as potent RORγ inverse agonists.
Wang T; Banerjee D; Bohnert T; Chao J; Enyedy I; Fontenot J; Guertin K; Jones H; Lin EY; Marcotte D; Talreja T; Van Vloten K
Bioorg Med Chem Lett; 2015 Aug; 25(15):2985-90. PubMed ID: 26048789
[TBL] [Abstract][Full Text] [Related]
40. Discovery of Chromane-6-Sulfonamide Derivative as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist.
Chen L; Su M; Jin Q; Wang W; Wang CG; Assani I; Wang MX; Zhao SF; Lv SM; Wang JW; Sun B; Li Y; Liao ZX
J Med Chem; 2021 Nov; 64(21):16106-16131. PubMed ID: 34723528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
